October 29th 2024
In the study, both migraine and gestational diabetes mellitus independently increase the risk of premature major cardiovascular and cerebrovascular events, with the highest risk observed among those with both conditions.
Get direct access to expert insight and perspective, and all the coverage of the key data presentations, straight from the conference floor in Madrid.
Mastering MS: Translating Evidence into Optimal Management Plans
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis - Current Treatment and Emerging Con...
November 12, 2024
Register Now!
Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes
View More
2024 Neuromuscular Summit
November 20, 2024
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management
View More
Study Findings Provide New Hope for Patients With Multiple Sclerosis
October 25th 2024Multiple sclerosis affects nearly 3 million patients worldwide; new research is helping pave the way for developing new therapies and medications that get at the defining mechanisms that trigger immune regulation loss of this unpredictable central nervous system disease.
The Potential of Device-Assisted Therapies in PD: Insights From the Phase 1/2 DIVE-I Trial
David Devos, MD, PhD, a neuropharmacologist at the University of Lille, in France, discussed positive data from an early-stage study assessing InBrain Pharma’s device-assisted therapy in Parkinson disease.
Expert Insight on Pivotal Phase 2 Data of AMX0035 in Wolfram Syndrome
Fumihiko Urano, MD, PhD, principal investigator of the phase 2 HELIOS trial, discussed some of the notable findings from the study, as well as the potential of AMX0035 to treat patients with Wolfram syndrome.
Patient Dosing Commenced for Phase 1/2 ArthemiR Trial of ATX-01 in Myotonic Dystrophy Type 1
ArthemiR, a placebo-controlled study, primarily evaluates the safety of ATX-01 in myotonic dystrophy type 1, with other assessments that include target engagement and measures associated with muscle function.
Phase 3 ENSURE Program of Vidofludimus Calcium Continues Following Positive Futility Analysis
An IDMC review of unblinded interim data was positive and advised that the trials continue as planned, with time to first relapse up to 72 weeks as the primary end point.
Revised McDonald Diagnostic Criteria Signals New Era in Multiple Sclerosis Treatment
October 22nd 2024The 2024 revisions to the McDonald diagnostic criteria for multiple sclerosis (MS) mark a significant advancement in the early detection and diagnosis of the disease, with new biomarkers and a broadened scope that may lead to earlier intervention and improved patient outcomes.
Understanding Nipocalimab’s Impact on Myasthenia Gravis Using MG-ADL
Constantine Farmakidis, MD, an associate professor of neurology at the University of Kansas Medical Center, provided clinical commentary on a subanalysis of a phase 3 study assessing nipocalimab, an investigational agent, in generalized myasthenia gravis.
Details Behind the Phase 3 MyClad Study of Cladribine in Myasthenia Gravis
Study investigator Henry Kaminski, MD, provided clinical insight on a unique trial assessing the efficacy and safety of oral cladribine tablets, an FDA-approved medication for multiple sclerosis, in patients with myasthenia gravis.
New Published Guideline Provides Recommendations for Primary Stroke Prevention Across Life Span
October 21st 2024The new guideline emphasized the importance of screening for risk factors and promoted healthy lifestyle changes to reduce the risk of stroke, which impacts over half a million patients in the United States.
Clinical Insights From Phase 3 VIVACITY-MG3 Study of Nipocalimab in Generalized Myasthenia Gravis
Tuan Vu, MD, a professor of neurology at the University of South Florida, provided brief commentary on topline data of the phase 3 VIVACITY-MG3 study presented at AANEM 2024.